initiated, funded and developed by Takeda
Adverse Event reporting information can be found at the bottom of the page
initiated, funded and developed by Takeda
Adverse events should be reported to the Medicines and Healthcare products Regulatory Agency. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Takeda at: AE.GBR-IRL@takeda.com.
ELVANSE®(lisdexamfetamine dimesylate)
INTUNIV®▼(guanfacine hydrochloride)
EQUASYM XL®(methylphenidate hydrochloride)